Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + abiraterone + cabazitaxel + enzalutamide
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a **quadruple drug combination** used in clinical research and oncological management of metastatic castration-resistant prostate cancer (**mCRPC**). It includes: - **prednisone**, a synthetic glucocorticoid corticosteroid mainly used to prevent excess mineralocorticoid effects of abiraterone and for immunosuppression. - **abiraterone**, a CYP17 inhibitor, targeting androgen biosynthesis. - **cabazitaxel**, a semi-synthetic taxane that inhibits microtubule depolymerization, acting as a cytotoxic agent. - **enzalutamide**, a potent androgen receptor inhibitor, blocking androgen receptor signaling. This combination seeks to maximize antitumor efficacy by concurrently blocking androgen production (abiraterone), androgen receptor signaling (enzalutamide), and by adding cytotoxic effects (cabazitaxel), all under the immunomodulation of prednisone. Clinical trial evidence supports efficacy for abiraterone/prednisone + cabazitaxel, with additional studies exploring the pharmacodynamic and pharmacokinetic interactions with enzalutamide included[1][2][4][5][7][10]. Developers and manufacturers correspond to each agent’s primary company; no single developer exists for the precise four-drug combination.
- Other names
- prednisone + abiraterone + cabazitaxel + enzalutamide
02
Targets
AR (Adrenergic receptors)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on prednisone + abiraterone + cabazitaxel + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + abiraterone + cabazitaxel + enzalutamide.